2016
2017
2018
2019
2020
Nivolumab
monotherapy
PDL1+
CheckMate-026
Q3 2016
Pembrolizumab
monotherapy
>50% PDL1+
Keynote 024
Q2 2016
MYSTIC
Q1 2017
Durvalumab
±
tremelimumab vs
SoC
Pembrolizumab +
platinium /
pemetrexed (non-
squamous)
Keynote 189
Q3 2017
Avelumab mono
vs Pt doublet
PD-L1+
JAVELIN lung 100
Q1 2018
Atezolizumab +
chemo
±
bevacizumab
vs chemo +
bevacizumab
IMpower 150
Q1 2017
Nivolumab mono vs
Niv + Ipi vs
Niv + Pt doublet vs
Pt doublet
CheckMate-227
Q1 2018
Pembrolizumab
monotherapy
>1% PDL1+
Keynote 042
Q2 2018
Atezolizumab
monotherapy
all histologies
PDL1+
Impower 110
Q2 2018
Atezolizumab +
chemo
IMpower 130 (non-
SCC)
Impower 131 (SCC)
Q3 2018
Durvalumab
±
tremelimumab
vs SoC
NEPTUNE
Q4 2018
Ipilimumab +
paclitaxel +
carboplatin
squamous
CA184-153
Q3 2019
PD1/PDL1
Monotherapy
CTLA4 + PD1
PD1 or PDL1
CT Combo
Legend
Projected read-out of many phase 3 anti PD1/PDL1 combination trials
in 1L advanced NSCLC (>15’000 patients)
Soria, ESMO 2016
